
|Videos|March 11, 2022
Study shows feasibility of incorporating hereditary cancer risk assessments into community urology practices
Author(s)Urology Times staff
“The traction on this, I think, is really rather remarkable,” says Neal D. Shore, MD, FACS.
Advertisement
In this video, Neal D. Shore, MD, FACS, discusses the findings of the study, “Hereditary cancer risk assessment in the community urology practice setting,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












